Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors.Bode, C.M., Boezio, A.A., Albrecht, B.K., Bellon, S.F., Berry, L., Broome, M.A., Choquette, D., Dussault, I., Lewis, R.T., Lin, M.H., Rex, K., Whittington, D.A., Yang, Y., Harmange, J.C.
(2012) Bioorg Med Chem Lett 22: 4089-4093
- PubMed: 22595176
- DOI: https://doi.org/10.1016/j.bmcl.2012.04.072
- Primary Citation of Related Structures:
4DEG, 4DEH, 4DEI
- PubMed Abstract:
Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small molecule drug discovery. Herein, we report the discovery of a structurally diverse series of carbon-linked quinoline triazolopyridinones, which demonstrates nanomolar inhibition of c-Met kinase activity. This novel series of inhibitors exhibits favorable pharmacokinetics as well as potent inhibition of HGF-mediated c-Met phosphorylation in a mouse liver pharmacodynamic model.
Amgen Inc., 360 Binney St., Cambridge, MA 02142, USA. firstname.lastname@example.org